<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>4(1)</volume><submitter>Mena Lora AJ</submitter><pubmed_abstract>Broad-spectrum antimicrobials are commonly used without indication and contribute to antimicrobial resistance (AMR). We implemented a syndrome-based stewardship intervention in a community hospital that targeted common infectious syndromes and antipseudomonal beta-lactam (APBL) use. Our intervention successfully reduced AMR, &lt;i>C. difficile&lt;/i> rates, use of APBLs, and cost.</pubmed_abstract><journal>Antimicrobial stewardship &amp; healthcare epidemiology : ASHE</journal><pagination>e31</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10945933</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Impact of a syndrome-based stewardship intervention on antipseudomonal beta-lactam use, antimicrobial resistance, &lt;i>C. difficile&lt;/i> rates, and cost in a safety-net community hospital.</pubmed_title><pmcid>PMC10945933</pmcid><pubmed_authors>Mena Lora AJ</pubmed_authors><pubmed_authors>Burgos R</pubmed_authors><pubmed_authors>Takhsh E</pubmed_authors><pubmed_authors>Bleasdale SC</pubmed_authors><pubmed_authors>Krill C</pubmed_authors><pubmed_authors>Huber D</pubmed_authors><pubmed_authors>Hunt AE</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Ali M</pubmed_authors><pubmed_authors>Sanchez L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Impact of a syndrome-based stewardship intervention on antipseudomonal beta-lactam use, antimicrobial resistance, &lt;i>C. difficile&lt;/i> rates, and cost in a safety-net community hospital.</name><description>Broad-spectrum antimicrobials are commonly used without indication and contribute to antimicrobial resistance (AMR). We implemented a syndrome-based stewardship intervention in a community hospital that targeted common infectious syndromes and antipseudomonal beta-lactam (APBL) use. Our intervention successfully reduced AMR, &lt;i>C. difficile&lt;/i> rates, use of APBLs, and cost.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2025-05-29T22:17:04.981Z</modification><creation>2025-05-29T22:17:04.981Z</creation></dates><accession>S-EPMC10945933</accession><cross_references><pubmed>38500719</pubmed><doi>10.1017/ash.2024.28</doi></cross_references></HashMap>